Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | NRAS Q61L |
Therapy | ERAS-007 |
Indication/Tumor Type | liver cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NRAS Q61L | liver cancer | sensitive | ERAS-007 | Preclinical - Cell culture | Actionable | In a preclinical study, ERAS-007 (ASN007) treatment inhibited proliferation of a liver cancer cell line harboring NRAS Q61L in culture (PMID: 34337566). | 34337566 |
PubMed Id | Reference Title | Details |
---|---|---|
(34337566) | ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. | Full reference... |